Capricor Therapeutics, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-40.7M | $-33.9M | $-30.2M | $-24.6M | $-25.9M | $-24.4M | $-7.1M | $-12.6M |
| Depreciation & Amortization | $561.8K | $534.7K | $502.6K | $494.7K | $486.3K | $405.5K | $375.7K | $361.2K |
| Depreciation | $561.8K | $534.7K | $502.6K | $494.7K | $486.3K | $405.5K | $375.7K | $361.2K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | — | — | — | — | — | — | $2.3M | $2.1M |
| Net Cash from Operating Activities | $-31.5M | $-29.3M | $-23.6M | $-19.7M | $-20.1M | $-6.4M | $-14.8M | $-11.6M |
| Investing Activities | ||||||||
| Capital Expenditures | $4.1M | $5.1M | $1.7M | $55.8K | $287.7K | $896.0K | $488.8K | $9.1K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-48.8M | $-154.6M | $43.1M | $16.0M | $14.5M | $23.9M | $-123.4M | $2.0M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $-4.2M | $1.5M | $248.8M | $7.0K | $19.6K | $50.4K | $81.1M | $67.3M |
| Net Change in Cash | — | — | — | — | — | — | — | — |
| Free Cash Flow | $-35.5M | $-34.4M | $-25.2M | $-19.7M | $-20.4M | $-7.3M | $-15.3M | $-11.7M |